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Abstract 
Aims 
Post-transplant thrombotic microangiopathy (TMA) is a rare and clinically challenging finding 
in renal transplant biopsies. In addition to recurrent atypical haemolytic uremic syndrome 
(aHUS), TMA in renal transplants is associated with various conditions, such as calcineurin-
inhibitor (CNI) treatment, antibody-mediated rejection (ABMR), viral infections, sepsis, preg-
nancy, malignancies or surgery. The therapeutic implications of this diagnosis are consider-
able. In order to better understand post-transplant TMA and to identify histological or clinical 
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differences between associated causes, we conducted a multi-centre retrospective study. 
Methods and Results 
Clinical parameters and transplant renal biopsy findings from 81 patients with TMA were 
analysed. Biopsies from 38 patients were also analysed by electron microscopy. Based on 
clinical-pathological correlation, TMA was attributed to a main aetiology, whenever possible.  
TMA occurred at a median of 30 days post-transplantation. Systemic features of TMA were 
present in only 18%. 22% of cases were attributed to CNI and 11% to ABMR. Although other 
potentially contributing factors were found in 56% of patients, in most cases (63%) no clearly 
attributable cause of TMA was identified. Histological differences between groups were min-
imal. Detection of ultrastructural features usually associated with ABMR may help establish 
ABMR as the cause of TMA. 
Conclusions 
Although CNI and ABMR appear to be the main contributors to post-transplant TMA, aetiol-
ogy of most cases is likely multifactorial and TMA cannot be unequivocally attributed to a 
single underlying aetiology. Morphological features of TMA are not discriminating but elec-
tron microscopy may help identify ABMR-associated TMA.  
 
Key words 
Thrombotic microangiopathy, kidney transplantation, antibody mediated rejection, 
calcineurin inhibitor, electron microscopy 
 
Introduction 
Thrombotic microangiopathy (TMA) is a condition in which there is endothelial damage in 
small vessels due to a variety of aetiologies, resulting in thrombosis. The kidney is often af-
fected. The clinical picture associated with TMA varies and may or may not present with the 
classical triad of haemolytic uremic syndrome (HUS) including thrombocytopenia, haemolytic 
anaemia and renal dysfunction. Shiga-toxin producing E.coli and S.pneumoniae associated 
HUS account for most of the typical forms of HUS, and for the great majority of HUS in chil-
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dren. Atypical HUS (aHUS) results from inherited or acquired dysregulation of the alternative 
pathway of complement  activation (reviewed in (1)). Thrombotic thrombocytopenic purpura 
(TTP) represents the third main clinical condition associated with TMA, caused by deficiency 
of ADAMTS13. There are many other potential causes of TMA, and, to complicate the pic-
ture, the morphological findings also vary: Some cases show acute thrombotic changes 
while chronic microangiopathic lesions dominate in others (2).  
TMA in renal transplant biopsies reflects either recurrence of the underlying disease or a de 
novo complication. De novo TMA is seen in 0.8% to 14% of renal transplant biopsies (3, 4). 
Various extrinsic risk factors, which potentially injure the endothelium and thereby trigger 
TMA, are found in kidney transplant recipients. Many studies focus on calcineurin-inhibitor 
(CNI) treatment as a cause of post-transplant TMA (4-11) while more recently antibody-
mediated rejection (ABMR) has been considered to be the main trigger for TMA in some 
studies (12, 13). 
In some cases however, glomerular and/or arteriolar thrombi are seen in the absence of any 
other characteristic histological features of ABMR thus it is unclear whether these cases are 
related to ABMR, CNI toxicity, recurrent disease or other known aetiologies of TMA. Clinical 
diagnosis is further complicated by the fact that the classical triad of HUS is often lacking in 
post-transplant TMA (12).   
In the absence of microvascular inflammation, a diagnosis of ABMR-related TMA requires 
the presence of 2 of the 3 following features: C4d-positivity, donor-specific antibodies (DSA) 
or increased expression of ABMR-related transcripts (14). C4d as a diagnostic marker, how-
ever, is limited by its low sensitivity (15), and validated transcript-analysis is not widely avail-
able. Previous studies on small numbers of patients suggested that isolated glomerular 
thrombi without arteriolar involvement may help identify ABMR-related TMA, but significant 
morphological overlap with other causes of TMA was recorded (12, 16).  
Identifying the underlying cause of TMA in renal transplant biopsies can be particularly chal-
lenging yet the therapeutic implications are considerable. The Banff Working Group for TMA 
has called for more studies to address the morphological features of TMA in various settings 
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(14). The aim of this study was to give a comprehensive picture of TMA in renal transplant 
patients and to identify underlying causes based on retrospective analysis and careful corre-
lation of pathological and clinical data. Here, we present the largest multi-centre study to 
date on post-transplant TMA, including 264 biopsies from 81 patients.  
 
Methods 
Study design and data collection 
Four UK transplant centres contributed to this retrospective study. The study met approval 
from the National Research Ethics Service (REC reference 14/EM/1245; 10 Nov 2014) and 
from all site-specific Departments of Research and Development. 
Histopathology electronic archives were searched for kidney transplant biopsies showing 
TMA, using search terms "thrombotic microangiopathy", “thrombosis“, “thrombus“. For the 
purposes of this study we specifically selected cases showing acute thrombotic 
microangiopathy, regardless of co-existing chronic/ non-thrombotic lesions. Thus, all cases 
showed thrombus, defined as presence of thrombotic material (platelet and/or fibrin) within 
glomerular capillaries, arterioles or arteries (figure 1). The first biopsy showing TMA is re-
ferred to as the index-biopsy. Banff lesion scores, result of C4d stain, main biopsy diagnoses 
and the following characteristics of TMA were recorded: Presence or absence of thrombi in 
glomeruli, arterioles and arteries; proportion of affected glomeruli and segmental or global 
extent of TMA in glomeruli. In addition, presence or absence of the following non-thrombotic 
lesions was assessed: mesangiolysis, fragmented red blood cells, collapse or bloodless ap-
pearance in glomeruli; intimal oedema, fragmented red blood cells and intramural fibrin in 
arterioles and arteries as well as presence or absence of onion skin lesions and fibrous inti-
mal thickening without elastosis in arteries. Main diagnosis for previous or subsequent biop-
sies and presence of TMA in subsequent biopsies was also recorded. In total, 81 patients 
with 264 transplant kidney biopsies were included (figure 2). Baseline clinical variables are 
listed in table 1 and clinical variables related to the index-biopsy in table 2. 
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Clinical-pathological classification of TMA cases 
Based on retrospective integration of clinical and histological parameters we assigned the 
most likely cause of TMA to every case if possible: Antibody-mediated rejection related TMA 
(ABMR-TMA) required positive donor-specific anti-HLA antibodies (DSA) at the time of in-
dex-biopsy, plus either capillaritis+glomerulitis>1, C4d>1 (excluding ABO-incompatible cas-
es), or Banff v3 transmural arteritis. Cases with high CNI-level at the time of index-biopsy 
and histologically C4d negative TMA with no other features of ABMR, and no other obvious 
reason for TMA were designated as CNI-related TMA (CNI-TMA). Definition of high CNI-
level was subject to local policy. Cases with other clear causes for TMA were designated 
OTHER-TMA. All other cases were classified as uncertain (UNCERTAIN-TMA).   
 
Electron microscopy  
Electron microscopy (EM) results were available for multiple biopsies from 38 patients, not 
necessarily corresponding to the index-biopsy. The following EM parameters, addressing 
signs of both acute and chronic endothelial damage, were compared between TMA groups: 
Mean and maximum number of peritubular capillary (ptc) basement membrane layers in at 
least 10 examined ptc (48 and 49 biopsies, respectively), presence of glomerular basement 
membrane double contours (44 biopsies), glomerular endothelial swelling (42 biopsies), lam-
ina rara interna expansion (46 biopsies), presence of intracapillary cells in glomeruli (39 bi-
opsies) and loss of glomerular endothelial cell fenestration (25 biopsies).  
 
Statistics 
Data were collected and analysed with STATA® version 14. Categorical data are given as 
absolute numbers and percentage and were compared using Fisher’s exact test. Continuous 
variables in tables are expressed as mean ± standard-deviation or median and interquartile 
range for skewed data. Continuous variables were compared using Wilcoxon or Kruskal 
Wallis test and post hoc analysis with Dunn’s test and Bonferroni correction of p-values for 
multiple pairwise comparisons for not normally distributed variables. P-values <0.05 were 
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regarded statistically significant. Prism® version 7 was used for graphic presentations. 
 
Results 
Patient characteristics 
There were 81 patients with post-transplant TMA in the study with clinical parameters shown 
in table 1 (baseline data) and table 2 (related to the index-biopsy). Selected Banff lesion 
scores as well as the main histological diagnosis in index-biopsies are shown in table 3. Pa-
tients were transplanted between 2003 and 2014 with a median follow up of 669 days. Mean 
age at transplantation was 45 years, 85% received their first kidney transplant. 14% had pre-
existing DSA. 31% of patients lost their graft within the follow up period and 4% died with a 
functioning graft. At the time of index-biopsy 17% of patients had non donor-specific anti-
HLA antibodies, 23% had DSA.  
The primary renal disease was frequently unknown (21%) and nephrosclerosis/hypertension 
as underlying renal disease was recorded in 5% of patients. Atypical HUS was clinically as-
sumed in one patient; genetic testing did not show clearly known pathologic mutations in 
CFI, CFH, CD46, C3 and CFB genes but heterozygosity for a variant of uncertain signifi-
cance in the CFI gene. 
 
Characteristics of TMA 
25% of patients had TMA in more than one biopsy. Signs of systemic TMA (defined as pres-
ence of both schistocytes and thrombocytopenia) were seen in 18% of patients at the time of 
presentation: Schistocytes were present in 18% of patients, drop in platelets was seen in 
33%. Median time to diagnosis of TMA post-transplant was 30 days (IQR 9-250), 76% of 
patients had TMA within the first year. The time between transplantation and TMA diagnosis 
did not differ significantly between recipients of deceased, living ABO compatible, or living 
ABO incompatible transplants, nor did it correlate with the cold ischemia time. TMA was 
seen in 1.3 to 2.6% of all transplant biopsies within the study period at the different centres. 
Histological features of TMA are shown in table 4. 
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Clinical-pathological classification of TMA cases 
Based on integration of clinical and histological parameters a single most likely aetiology 
could be assigned in 37% (30/81) of patients: TMA was attributed to ABMR in 11% (9) of 
patients (ABMR-TMA), all of which had DSA at the time of index-biopsy. TMA was attributed 
to CNI-toxicity in 22% (18) of patients (CNI-TMA), all of which had high CNI-levels at the 
time of index-biopsy (or immediately before biopsy in one patient). TMA was attributed to 
other clear causes in 3 patients (OTHER-TMA: hypertension-associated TMA, recurrent SLE 
with antiphospholipid syndrome and likely recurrent aHUS, respectively). In 63% (51) the 
aetiology of TMA remained uncertain (UNCERTAIN-TMA).  
 
Additional contributing factors 
For every patient the presence or absence of any further factors potentially contributing to 
TMA were recorded (excluding those factors which determined the assumed main aetiology 
of TMA in individual cases). 56% (45) of patients had one or more potentially contributing 
factor, none of which could be confidently identified as the main aetiological reason for TMA. 
Details are shown in figure 3.  
 
Electron microscopy (EM) 
EM was available for 38 patients and results are shown in figure 4. The limited number of 
EM results from the index-biopsies precluded sub-analysis of EM specimens from index-
biopsies only and therefore includes even EM done on follow up biopsies. Due to small 
sample size and repeat biopsies from individual patients statistical analysis was not per-
formed.  
 
Comparison between TMA groups 
Both TMA characteristics and clinical parameters were compared between four clinical-
pathological TMA groups (tables 1, 2 and 4). The only significantly different parameter on 
histology was the extent of TMA in glomeruli which was mostly segmental in CNI-TMA (93% 
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cases segmental). Time from transplantation to index-biopsy was shortest in CNI-TMA and 
OTHER-TMA. By definition, ABMR-TMA had more DSA at biopsy and CNI-TMA had high 
CNI levels at biopsy. Neither mean GFR at index-biopsy nor at follow up were different be-
tween groups. The proportion of graft losses was highest in ABMR-TMA but did not signifi-
cantly differ between groups.  
We also limited the analysis to comparison between ABMR-TMA and CNI-TMA. Histological-
ly, the extent of TMA in glomeruli was significantly different (less frequently global involve-
ment of glomeruli in CNI-TMA). Also, mesangiolysis and fragmented red blood cells in glo-
meruli were significantly more frequent in ABMR-TMA. Clinically, CNI-TMA cases less fre-
quently had a previous kidney transplant or anti-HLA antibodies prior to transplantation.  
 
Focus on cases in which aetiology of TMA remained uncertain 
In the majority of patients (51/81, 63%) no unequivocal underlying aetiology could be deter-
mined (UNCERTAIN-TMA). In 37 patients within this group one or more potentially contrib-
uting factors, as described above, were present (figure 3). Of note, 10 patients within this 
group showed morphological features of ABMR in their index-bx (either g+ptc>0 and C4d 
positive or g+ptc>1 and C4d negative plus Banff v3 lesion score in 2 patients) but did not 
have DSA. Nine more patients had DSA but neither microvascular inflammation nor C4d-
positivity (or C4d-positivity in the context of ABOi transplantation, precluding its use to as-
sign cases to ABMR). Together, these 19 cases showed some but not all features of ABMR 
so were not formally assigned to the ABMR-TMA category. 
Electron microscopy was available for 26 patients (38 biopsies) from the UNCERTAIN-TMA 
group, not necessarily taken at the time of index-biopsy. In order to simplify assessment of 
ultrastructural changes in this group we combined five dichotomous EM-parameters (glo-
merular endothelial swelling, lamina rara interna expansion, loss of endothelial fenestration, 
presence of glomerular double contours and presence of intra-capillary cells in glomeruli) if 
available, to a score: no EM changes; mild: changes in 1-2 parameters; moderate: changes 
in 3 parameters; severe: changes in 4-5 parameters. 
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Of 4 cases that had high CNI levels at index-biopsy as a possibly contributing factor, none 
had more than mild EM-changes. 3 of 4 cases with a morphological picture within the 
ABMR-spectrum (but without evidence of DSA) had moderate or severe EM-changes. Pres-
ence of DSA at the time of index-biopsy was not per se associated with more severe EM 
changes in this subgroup (4/6 cases with DSA at index-biopsy had only mild EM changes). 
In cases for which no contributing factor was identified and EM was available (n=6), EM 
changes ranged from absent to severe without any discernible pattern.  
 
Discussion 
Thrombotic microangiopathy following kidney transplantation is a relatively rare microscopic 
finding with multiple aetiologies. Prevalence of de novo TMA after kidney transplantation 
varies considerably in the literature, ranging from 0.8 to 14% (3, 4). This might even be an 
underestimate as clinical manifestations, which could be a trigger for transplant biopsy, are 
not present in most cases. In addition, standardised histologic criteria for microangiopathic 
lesions are lacking. The clinical challenge of TMA in the transplant setting is the number of 
potential underlying causes with conflicting therapeutic implications. Integration of clinical, 
serological and histological findings therefore is paramount in order to ascertain a firm diag-
nosis.  
Against this background we carried out a large, multi-centre retrospective study of clinical 
and morphological findings in post-transplant TMA. We limited our analysis to cases with 
frank thrombotic lesions and found that: TMA occurred at a median of 30 days post-
transplantation in 2% of transplant kidney biopsies. Timing was not influenced by transplant 
type (living versus deceased) or cold ischemia time. Systemic features of TMA were only 
present in 18%. CNI-treatment accounted for 22% of cases and ABMR for 11%. Although 
potentially contributing factors were identified in overall 56% of patients, in most cases 
(63%) there was not one clearly attributable cause of TMA even after careful integration of 
histological and clinical features. Likely, ABMR does account for more cases but either typi-
cal morphological features or DSA are lacking, precluding a definite diagnosis. Histological 
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differences between causes were limited. Detection of features usually associated with 
ABMR by electron microscopy may help establish ABMR as the cause of TMA. 
Our study concurs with previous reports in noting that de novo post-transplant TMA fre-
quently occurs within the first months after transplantation (13, 17) and most often without 
systemic manifestations (12). A drop in platelet count was observed in 33% of patients, alt-
hough in the post-transplant setting, plasmapheresis or immunosuppressive drugs in itself 
can reduce platelet count. Schistocytes were seen in 18% and a combination of both was 
observed in 18%.  
Using strict criteria, CNI-treatment accounted for 23% of cases and ABMR for 11%. Howev-
er, another 23% of patients had either DSA alone or morphological features of ABMR alone. 
In the literature, the proportion of TMA-cases attributed to ABMR is variable and represents 
up to 55% of cases (12, 13, 18). In this study we used strict and up-to-date criteria, which 
might explain our lower percentage. Particularly in these morphologically ambiguous cases, 
analysis of ABMR-associated gene transcripts may help identify cases related to ABMR.  
Recurrent aHUS was suspected in one patient who did not have a clearly pathogenic muta-
tion but  a variant of uncertain significance in CFI gene. It is likely that some of the cases in 
this cohort may represent recurrent aHUS, where the cause of end-stage renal failure was 
either unknown or incorrect. Genetic testing for TMA susceptibility-genes was not widely 
available during the study period. Le Quintrec et al. found rare variants in complement regu-
latory genes (initially reported as pathogenic mutations) in 29% of patients with de novo 
post-transplant TMA, but not in a control group, suggesting that genetic variants may render 
a subset of patients susceptible to develop TMA in a post-transplant setting with increased 
endothelial stress for various reasons (1, 19).  
We identified one or more risk factors which likely contributed to TMA in 56% of patients. In 
most of these cases, none of the contributing factors could be unequivocally assigned as the 
underlying cause, either because not all defined diagnostic criteria were fulfilled, or the pic-
ture was too complex to identify one clear aetiology. Whilst the presence of one risk factor 
may not have been significant, in the presence of an abnormal complement response to 
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stimuli, this may be sufficient to trigger a TMA response. These findings underscore the 
complexity in transplanted patients where many potential causes either in isolation or in 
combination can trigger TMA.  
Comparison of light microscopic and clinical TMA-characteristics between ABMR- and CNI-
related TMA revealed only minor differences. This is in keeping with KDIGO guidelines for 
native biopsies, which do not recommend attribution of a given cause to TMA on the basis of 
histological features alone (2). 
Electron microscopy as an adjunct tool for early detection of ABMR has gained new atten-
tion recently (20-25). We and others have found that early endothelial changes such as en-
dothelial swelling, subendothelial widening and loss of endothelial fenestration, are more 
frequent in biopsies with evidence of ABMR and/or DSA compared to ABMR/DSA-negative 
biopsies (24, 26).  Haas and colleagues studied early ultrastructural changes in transplant 
renal biopsies with respect to ABMR. They infrequently found such changes in cases with 
CNI-toxicity in the absence of evidence of ABMR, and concluded that early ultrastructural 
glomerular changes seem to be relatively specific for ABMR (26). However, ultrastructural 
changes of CNI-toxicity have not been studied systematically. One may speculate that, in 
contrast to dose-dependent transient CNI-induced endothelial stress, DSA induce enduring 
endothelial damage and subsequently, structural remodeling of endothelium and basement 
membranes. Liapis et al. focused on peritubular capillary basement membrane multilayering 
in both native and transplant biopsies and found that chronic ABMR carried the highest risk 
for severe ptc multilayering although the latter was seen in native kidneys with chronic TMA 
(27). Here, we observed most pronounced endothelial and basement membrane changes in 
TMA cases attributed to ABMR. However, the mere presence of DSA was not per se asso-
ciated with these changes. In conclusion, ultrastructural abnormalities largely reflected the 
light microscopy findings and severe ultrastructural changes argue against acute CNI-
induced TMA. However, EM-results need to be interpreted with caution, as numbers of indi-
vidual parameters in each group were small or incomplete. Transcript analysis and 
ultrastructural analysis may be useful tools in distinguishing between CNI- and ABMR-
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induced TMA in cases where other diagnostic criteria fail to establish a clear diagnosis, and 
further investigation of both of these adjunct techniques would be worthwhile.  
Overall, the present study confirms that light microscopic histopathology alone gives little 
indication of the causes of post-transplant TMA. Careful clinical-pathological correlation is 
crucial with a substantial proportion of cases that continue to remain unclear or complex and 
multifactorial. The addition of both functional and genetic testing for complement abnormali-
ties may give insight into patients with TMA, even those who have an identified risk factor, in 
order to guide therapies, such as CNI avoidance in those more susceptible to endothelial 
dysregulation. Pathologists should provide a differential diagnosis of potential causes of 
TMA and emphasise that even identification of a potential trigger does not exclude an under-
lying genetic predisposition.  Future studies in order to improve diagnosis and patient man-
agement should include complement genotyping, ultrastructural examination and transcript 
analysis for ABMR-associated gene expression.   
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Figure legends 
 
Figure 1: Histological appearances of post-transplant TMA 
A: Thrombotic material is seen in a glomerular segment extending from the hilus (Jone’s 
Silver stain, original magnification x200). B: A glomerulus showing mesangiolysis with red 
blood cell extravasation (H&E, original magnification x200). C: Two small arterial branches 
showing subendothelial oedema and bloodless glomeruli (H&E, original magnifiaction x100). 
D: Subintimal oedema and red blood cell fragments are seen in a small artery (Jone’s Silver 
stain, original magnification x200). E: Subendothelial red blood cell fragments are seen in an 
arteriole (H&E, original magnification x400). F: A small artery showing subendothelial oede-
ma and fibrin (H&E, original magnification x200)  
 
Figure 2: Patient cohort and biopsy material 
The first biopsy showing TMA is defined as the patient’s index biopsy. Transplant biopsies 
before and after the index biopsy within the study period were also recorded (non-index bi-
opsies). 27 follow up biopsies showed TMA in addition to the index biopsy, which means that 
41% of all biopsies showed TMA.    
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Figure 3: Contributing factors 
In 56% of patients (45/81) one or more factors potentially contributing to TMA were found, 
which could not be assigned unequivocally as the main cause for TMA.  
In 14 patients in the UNCERTAIN-TMA group no contributing factor was identified, thus in 
these 14/81 patients (17%) aetiology of TMA remained entirely unclear. Histologically, 13 of 
those cases showed TMA in their index biopsy without microvascular inflammation and one 
showed Banff I acute cellular rejection. 
*Sum of numbers in parenthesis is higher than numbers of patients as a few cases have 
more than one contributing factor. 
 §Possible pro-thrombotic underlying conditions include history of scleroderma, history of 
malignant hypertension, history of detected Lupus anti-coagulant (but diabetes as underlying 
disease), history of SLE with Lupus anti-coagulant, history of antiphospholipid syndrome, 
donor history of scleroderma 
$Other factors include Treatment for tuberculosis (in 2 cases), de novo post-infectious glo-
merulonephritis, acute CMV-infection, lung transplant, pancreatic surgery, sepsis, histiocytic 
glomerulopathy of uncertain aetiology    
 
Figure 4: Ultrastructural changes in glomeruli and peritubular capillaries in different 
aetiological groups of TMA 
Ultrastructural changes in glomeruli and peritubular capillaries are shown. Both glomerular 
basement membrane and glomerular endothelial changes as well as peritubular capillary 
basement membrane multilayering (ptcbml) are most prominent in ABMR-TMA. In contrast, 
ultrastructural changes are infrequent in CNI-TMA. The limited number of samples in each 
group and inclusion of subsequent biopsies from individual patients precluded statistical 
analysis. Electron microscopy in the subgroup of UNCERTAIN-TMA is described in more 
detail in the results-section. 
GBM: Glomerular basement membrane; ptcbml: peritubular capillary basement membrane 
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multilayering. Total number of biopsies analysed in parenthesis.  
*No cases available from CNI-TMA group for this analysis 
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Tables 
Table 1: Patient details and baseline clinical data for all patients and compared between TMA-groups 
   Assumed main etiological groups    
 
All pa-
tients 
(n=81) 
total 
number of 
valid 
obser-
vations¶  
ABMR-
related 
TMA 
(n=9) 
total 
number of 
valid 
obser-
vations¶ 
CNI-
related 
TMA 
(n=18) 
total 
number of 
valid 
obser-
vations¶ 
other as-
sumed 
cause of 
TMA (n=3)
total 
number of 
valid 
obser-
vations¶ 
cause of 
TMA un-
clear 
(n=51) 
total 
number of 
valid 
obser-
vations¶ 
p-
value* 
p-
value† 
Mean age at tx; 
y 45 ± 13 81 43 ± 6 9 40 ± 12 18 26 ± 9 3 49 ± 13 51 0.012 n.s. 
Recipient gen-
der; fe-
male/male 
43%/57% 81 67%/ 33% 9 
28%/ 
72% 18 
100%/ 
0% 3 
41%/ 
59% 51 0.052 0.064 
Mean donor 
age; y 48 ± 13 55 44 ± 12 4 48 ± 12 15 49 1 49 ± 15 35 n.s. n.s. 
Type of trans-
plant 
 81  9  18  3  51 n.s. 0.061 
deceased in-
cluding pancre-
as/ 
kidney  
52%  22%  50%  33%  59%    
living, ABOc 36%  56%  46%  67%  27%    
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living ABOi 12%  22%  6%  0%  14%    
Re-
transplanted 15% 79 50% 8 6% 18 50% 2 12% 51 0.011 0.02 
Induction  79  8  18  2  51 0.001 0.000 
Basilixi- 
mab 48% 
 0%  83%  100%  41%    
Campath 34%  50%  6%  0%  43%    
PlEx/Campath/
Rituximab 5% 
 25%  0%  0%  4%    
Basilixi- 
mab/Rituximab 4% 
 0%  6%  0%  4%    
other/unknown 9%  25%  6%  0%  8%    
Mean CIT; h 11.1 ± 7.2 60 9.4 ± 8.3 4 8.1 ± 6.4 17 8.3 ± 8.1 2 12.9 ± 7.4 37 n.s. n.s. 
Mean number 
of HLA-
mismatches 
3.1 ± 1.6 80 3.8 ± 1.5 9 2.9 ± 1.7 17 3 ± 0 3 3.1 ±1.7 51 n.s. n.s. 
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Pre-existing 
anti-HLA anti-
bodies 
 78  9  18  3  48 0.000 0.000 
No antibodies 65%  11%  89%  100%  65%    
anti-HLA, non 
donor-specific 21% 
 11%  11%  0%  27%    
donor-specific  14%  78%  0%  0%  8%    
Original dis-
ease 
 81  9  18  3  51 n.s. n.s. 
Glomeulo-
nephritis 16% 
 11%  17%  33%  16%    
Vasculitis 5%  0%  6%  0%  6%    
SLE/APLS 6%  11%  0%  33%  6%    
Systemic scle-
rosis 1% 
 0%  6%  0%  0%    
FSGS 4%  0%  11%  0%  2%    
Diabetes 14%  11%  0%  0%  20%    
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Nephro-
sclerosis/ hy-
per-tension 
5%  0%  6%  0%  6%    
CNI-toxicity 2%  0%  0 %  0%  4%    
Reflux/obstruc-
tion/pyelonephri
tis 
9%  33%  17%  0%  2%    
Hereditary renal 
disease‡ 17% 
 22%  22%  0%  16%    
Oth-
er/unknown§ 21% 
 11%  17%  33%  24%    
 
 
 
 
 
Percentage may not sum to 100 due to rounding 
¶Total number of valid observations may vary from total number of cases within respective group due to missing values 
Tx, transplantation; ABOc, Blood group ABO compatible; ABOi, Blood group ABO incompatible; bx, biopsy; PlEx, Plasma exchange; CIT, cold 
ischemia time; SLE, systemic lupus erythematosus; APLS, antiphospholipid syndrome; FSGS, focal segmental glomerulosclerosis; CNI, 
calcineurin inhibitor 
*Comparison between all groups; † comparison between ABMR- and CNI-related TMA 
‡ Alport’s, cystic diseases and developmental kidney defects; § one of which with assumed but not genetically confirmed aHUS in childhood, 
one with end-stage kidney disease due to nephrocalcinosis, one with possible but unconfirmed systemic sclerosis, all other cases in this group 
unknown 
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Table 2: Clinical data related to the index-biopsy for all patients and compared between TMA-groups 
 
   Assumed main etiological groups    
 
All pa-
tients 
(n=81) 
total num-
ber of valid 
obser-
vations¶   
ABMR-
related 
TMA 
(n=9) 
total 
number 
of valid 
obser-
vations¶  
CNI-related 
TMA 
(n=18) 
total 
number 
of valid 
obser-
vations¶  
other as-
sumed 
cause of 
TMA (n=3) 
total num-
ber of 
valid 
obser-
vations¶  
cause of 
TMA un-
clear 
(n=51) 
total number 
of valid 
obser-
vations¶   
p-
value* 
p-
value† 
Median 
time from 
tx to index 
bx; d (IQR) 
30 
(9-250) 81 
17 
(9-716) 9 
10 
(9-16) 18 
7 
(6-1186) 3 
89  
(17-411) 51 0.0096 n.s. 
Median 
length of 
follow-
up/IQR; d 
669 
(337-
1121) 
81 457 (47-1533) 9 
955 
(532-1656) 18 
376 
(30-730) 3 
621 
(243-1035) 51 n.s. n.s. 
Immuno-
suppr.at 
index bx 
 78  9  17  2  50 n.s. n.s. 
MMF, 
Pred, CsA 4% 
 11%  6%  0%  2%    
MMF, 
Pred, Tac 55% 
 56%  65%  100%  50%    
Tac, Pred, 
Aza 13% 
 11%  18%  0%  12%    
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Tac only 9%  0%  6%   0%  12%    
Tac, MMF 9%  0%  0%  0%  14%    
Pred, CsA, 
Aza 3% 
 0%  6%  0%  2%    
Tac, Pred 6%  22%  0%  0%  6%    
Tac, other 1%  0%  0%  0%  2%    
Anti-HLA 
antibodies 
at index bx 
 78  9  18  2  49 0.000 0.000 
No anti-
bodies  60% 
 0%  89%  100%  60%    
anti-HLA, 
non donor-
specific 
17%  0%  11%  0%  22%    
donor-
specific  23% 
 100%  0%  0%  18%    
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Mean GFR 
at index bx 
(if not on 
HD); 
ml/min 
26 ± 13 66 21 ± 7 7 28 ± 15 12 24 ± 11 3 27 ± 14 44 n.s. n.s. 
HD at in-
dex bx 19% 81 22% 9 33% 18 0% 3 14% 51 n.s. n.s. 
Mean GFR 
at follow-
up (if not 
graft loss); 
ml/min 
40 ± 18 53 40 ± 19 3 38 ± 16 16 58 ± 21 2 40 ± 19 32 n.s. n.s. 
Graft loss 31% 81 44% 9 11% 18 33% 3 35% 51 n.s. 0.073 
Drop in 
platelets at 
index bx 
33% 80 22% 9 33% 18 50% 2 33% 51 n.s. n.s. 
Schisto-
cytes at 
index bx 
18% 67 11% 9 27% 11 100% 2 13% 45 0.037 n.s. 
Signs of 
systemic 
TMA at 
index bx 
18% 80 11% 9 17% 18 50% 2 18% 51 n.s. n.s. 
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Low serum 
comple-
ment at 
index bx 
33% 
18 
(un-
known/n
ot tested 
in 78%) 
50% 2 0% 2 0% 1 38% 13 n.s. n.s. 
Significant 
hyper-
tension at 
index bx 
7% 81 0% 9 6% 18 33% 3 8% 51 n.s. n.s. 
High CNI 
level at 
index bx 
33% 80 11% 9  94% 18  0% 2  16% 51 0.000 0.000 
CMV-
viremia at 
index bx 
5% 65 11% 9 0% 8 0% 2 4% 46 n.s. n.s. 
 
 
 
 
 
Percentage may not sum to 100 due to rounding 
¶Total number of valid observations may vary from total number of cases within respective group due to missing values or as variable does not 
apply to all patients 
*Comparison between all groups; † comparison between ABMR- and CNI-related TMA 
Tx, transplantation; bx, biopsy; MMF, mycophenolate mofetil; Pred, Prednisolone; CsA, Cyclosporin; Tc, Tacrolimus; Aza, Azathioprine; HD, 
hemodialysis; CNI, calcineurin inhibitor; IQR, interquartile range 
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Table 3: Main histological diagnosis in index-biopsies as well as microvascular inflammation, C4d- and DSA-status 
 
  Index-biopsies in Assumed main etiological groups 
Main histological 
diagnosis 
All index-biopsies 
(n=81) ABMR-related TMA (n=9) 
CNI-related TMA 
(n=18) 
other assumed 
cause of TMA 
(n=3) 
cause of TMA unclear 
(n=51) 
Mean MVI-score¶ 0.73 ± 1.3 1.2 ± 1.5 0.17 ± 0.5 0 0.88 ± 1.4 
C4d positive#, n 13/79 6/9 1 (ABOi)/18  0/3 6 (of which 2 ABOi)/49 
TMA as main diag-
nosis*; % (n) 77 (62) (5) § (18) (3) (36) 
TCMR Banff I or II; 
% (n) 2.5 (2) 0 0 0 (2) 
Banff III; % (n) 3.7 (3) (1) 0 0 (2) 
Histological fea-
tures in keeping 
with ABMR†; % (n) 
15 (12) (3) 0 0 (9) 
Other diagnosisǂ; % 
(n) 2.5 (2) 0 0 0 (2) 
DSA positive at in-
dex-bx**, n 18/78 9/9 0/18 
0/2 (DSA status 
unclear in 1) 9/49 
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Percentage may not sum to 100 due to rounding 
CNI, calcineurin inhibitor; TCMR, T-cell-mediated rejection; ABMR, Antibody mediated rejection; MVI, microvascular inflammation; DSA, donor-
specific antibodies 
*11 patients with borderline-changes in the background; † either g+ptc>0 and C4d>1 or g+ptc>1. In 4 patient there was evidence of chronic 
ABMR with Banff lesion score cg>1a ;  
ǂ acute pyelonephritis and histiocytic glomerulopathy of uncertain cause, respectively; § all C4d>1 
¶ Microvascular inflammation Banff ptc-score+Banff g-score; not significantly different between groups (p=0.052) 
# C4d positive=Banff C4d-score >1; significantly different between groups (p=0.002)   
** significantly different between groups (p<0.000) 
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Histological
 
featu
res of
 
TM
A
 
All
 TM
A
-
biop
sies
 
(n=108)
 
total
 n
u
m
-
be
r
 of
 
valid 
ob
se
r
-
vatio
ns ¶
 
 
AB
M
R
-
related
 
TM
A
 
(n=13)
 
total n
u
m
-
be
r
 of
 
valid
 
obse
r
-
vatio
ns ¶
 
 
CNI
-
related
 
TM
A
 
 
(n=23)
 
total 
n
u
m
be
r
 
of
 valid 
obse
r
-
vatio
ns ¶
 
 
 
other
 as-
su
m
ed 
cau
se
 of
 
TM
A
 (n
=4)
 
total 
n
u
m
be
r
 
of
 valid 
obse
r
-
vatio
ns ¶
 
 
cau
se
 of
 
TM
A
 
u
n
clear
 
(n=68)
 
total
 
n
u
m
be
r
 of
 
valid 
ob
ser
-
vatio
ns ¶
 
 
p-
valu
e
*
p-
val-
u
e†
 
TM
A present 
in glo
m
e
ruli
 
75%
 
108 
85%
 
13 
70%
 
23 
100%
 
4 
74%
 
68 
n.s. 
n
.s. 
Exte
nt
 of
 TM
A 
in glo
m
e
ruli;
 
seg
m
e
n
-
tal/global,
 if
 
TM
A present 
in glo
m
e
ruli
 
69%
/ 
31%
 
80 
45%
/ 55%
 
11 
93%
/ 
 7%
 
15 
50%
/
 
 
50%
 
4 
68%
/
 
 
32%
 
50 
0.036
 
0.021
 
M
edian p
ro
-
portio
n
 glo
-
m
e
ruli
 affe
ct
-
ed, if
 TM
A
 
prese
nt
 in
 
glom
eruli
 
(IQ
R)
 
11%
 
(6-29)
 
80 
13%
 
(8
-59)
 
11 
11%
 
(8-16)
 
15 
26%
 
(12-37)
 
4 
9%
 
(6-17)
 
50 
n.s. 
n
.s. 
P
re
se
n
ce
 of
 
e
xtra
-
glom
erula
r
 
TM
A
 
58%
 
104 
54%
 
13 
55%
 
22 
75%
 
4 
58%
 
65 
n.s. 
n
.s. 
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TMA present 
in arterioles 53% 107 54% 13 55% 22 75% 4 51% 68 n.s. n.s. 
TMA present 
in arteries 9% 105 0% 13 17% 23 0% 4 8% 65 n.s. n.s. 
Glomerular 
double con-
tours present 
10% 105 23% 13 0% 22 0% 4 12% 66 n.s. 0.044 
Mesangiolysis 
present 15% 108 39% 13 4% 23 0% 4 15% 68 0.055 0.016 
Fragmented  
RBCs in glo-
meruli present 
10% 108 23% 13 0% 23 0% 4 12% 68 n.s. 0.04 
Glomerular 
collape pre-
sent 
31% 105 46% 13 29% 21 25% 4 30% 67 n.s. n.s. 
Bloodless 
glomeruli pre-
sent 
32% 105 31% 13 29% 21 0% 4 36% 67 n.s. n.s. 
Intimal oede-
ma in arteries/ 
arterioles pre-
sent 
47% 104 54% 13 36% 22 50% 4 49% 65 n.s. n.s. 
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Fragmented 
RBCs in arter-
ies/ arterioles 
present 
24% 105 23% 13 13% 23 25% 4 28% 65 n.s. n.s. 
Intramural fi-
brin in arteries/ 
arterioles pre-
sent 
34 % 106 15% 13 35% 23 75% 4 35% 66 n.s. n.s. 
Fibrous intimal 
thickening in 
arteries pre-
sent 
11 % 105 15% 13 9% 23 0% 3 12% 66 n.s. n.s. 
 
 
Percentage may not sum to 100 due to rounding 
¶Total number of valid observations may vary from total number of cases within respective group due to missing values or as variable does not 
apply to all cases. In total, TMA was present in 108 biopsies but in one follow up biopsy with TMA no histological details were available.  
*Comparison between all groups; † comparison between ABMR- and CNI-related TMA 
TMA, thrombotic microangiopathy; ABMR, antibody mediated rejection; IQR, interquartile range 
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